Particle.news
Download on the App Store
4 ARTICLES
·
2d ago

AstraZeneca Deepens China Pact With $5.2 Billion CSPC Research Collaboration

AstraZeneca’s partnership with CSPC taps AI to advance chronic disease candidates against a backdrop of ongoing Chinese regulatory scrutiny.

China accounted for 12 per cent of AstraZeneca’s $54.1 billion group revenue last year
Image
Image
Image

Overview

  • Under the $5.2 billion agreement announced June 13, AstraZeneca will pay $110 million upfront plus up to $1.6 billion in development milestones and $3.6 billion in sales milestones to CSPC.
  • CSPC will deploy its Shijiazhuang-based AI platform to identify pre-clinical small molecule therapies for immunological and other chronic diseases.
  • AstraZeneca secures exclusive licence options to develop and commercialise any drug candidates emerging from the collaboration worldwide.
  • The deal builds on AstraZeneca’s March plan to invest $2.5 billion in a Beijing R&D hub and extends an earlier $2 billion cholesterol drug licence agreement with CSPC.
  • The expansion proceeds despite Chinese probes into alleged illegal drug imports and medical insurance fraud and the ongoing detention of Leon Wang, the company’s former head of international and China operations, since October 2024.